CLINICAL TRIAL: APPLE STUDY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项试验的目的是评估一种降脂剂(阿托伐他汀)对导致儿童系统性红斑狼疮(SLE)在成年后易发生心血管事件的动脉粥样硬化的疗效，评估使用阿托伐他汀对儿童进行中期(36个月)治疗的安全性，通过建立一个前瞻性跟踪的儿童SLE患者队列，进一步描述儿童SLE的病程，并建立一种机制，利用儿童关节炎和风湿学研究联盟(CARRA)(前儿童风湿学研究网络(PRRN))和杜克临床研究所(DCRI)进行罕见的儿童风湿性疾病的临床试验。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this trial are to assess the efficacy of a lipid-lowering agent (atorvastatin) on the development of atherosclerosis that predisposes children with SLE to cardiovascular events in adulthood, to assess the safety of intermediate-term (36 months) treatment of children with atorvastatin, to further characterize the course of SLE in children, by establishing a cohort of pediatric SLE patients to be followed prospectively, and to establish a mechanism for conducting clinical trials in rare pediatric rheumatic diseases using the Children's Arthritis and Rheumatology Research Alliance (CARRA) (formerly Pediatric Rheumatology Research Network (PRRN)) and the Duke Clinical Research Institute (DCRI).